NEW YORK, April 4, 2017 /PRNewswire/ -- Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Ankylosing Spondylitis in 13 Major Markets
Ankylosing Spondylitis (AkS) is a chronic, systemic inflammatory autoimmune disease. It primarily affects the sacro-iliac joints of the hip and pelvis, but extends to the axial skeleton. Patients experience low back pain and increased stiffness.
Read the full report: http://www.reportlinker.com/p04807850/Epiomic-Epidemiology-Series-Ankylosing-Spondylitis-Forecast-in-13-Major-Markets.htmlThis report provides the current prevalent population for Ankylosing Spondylitis across 13 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Turkey, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Ankylosing Spondylitis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.There are several features associated with Ankylosing Spondylitis, these include:- Psoriasis- Uveitis- IBD- Enthesitis- peripheral arthritis- Pulmonary fibrosis- CVD (aortic root / rheumatic heart / AV block and other conduction disorders)- Prostatitis (males) - Spinal ankylosis and fractureThis report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report. Reason to buy- Able to quantify patient populations in global Ankylosing Spondylitis market to target the development of future products, pricing strategies and launch plans. - Gain further insight into the prevalence of the subdivided types of Ankylosing Spondylitis and identify patient segments with high potential.- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.- Provide a level of understanding on the impact from specific co-morbid conditions on Ankylosing Spondylitis prevalent population.- Identify sub-populations within Ankylosing Spondylitis which require treatment.- Gain an understanding of the specific markets that have the largest number of Ankylosing Spondylitis patients.Read the full report: http://www.reportlinker.com/p04807850/Epiomic-Epidemiology-Series-Ankylosing-Spondylitis-Forecast-in-13-Major-Markets.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com__________________________Contact Clare: [email protected]US: (339)-368-6001Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/epiomic-epidemiology-series-ankylosing-spondylitis-forecast-in-13-major-markets-2017-2027-300434529.html